Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...

Mavacamten is a selective, reversible, allosteric cardiac myosin inhibitor. It is approved under the brand name Camzyos ® for the treatment of adults with symptomatic New York Heart Association class ...

Myqorzo is expected to be available by the second half of January 2026. The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic ...

BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline ...

Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...

NEW HYDE PARK, N.Y., Jan. 12, 2026 (GLOBE NEWSWIRE) -- CareMed (R) , an independent specialty pharmacy, has been selected as a pharmacy partner by Cytokinetics for MYQORZO (TM) (aficamten), indicated ...

Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...

Myqorzo and Redemplo approved in ChinaApproval of Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia ...

The FDA has approved Myqorzo (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is contraindicated with ...